SNS Insider Reveals Strategic Outlook for the U.S. Uveitis Treatment Market—Valued at USD 0.71 Billion in 2023—With the Nation Poised to Maintain North American Dominance Amid Rising Adoption ...

SNS Insider Reveals Strategic Outlook for the U.S. Uveitis Treatment Market—Valued at USD 0.71 Billion in 2023—With the Nation Poised to Maintain North American Dominance Amid Rising Adoption of ...

Ophthalmic pharmaceuticals has a diverse lineup of products, including Xipere, Vyzulta, and Lotemax that treat different complications. With over 100 products, B&L has the largest portfolio of eye ...

See the latest Bausch & Lomb Corp stock price (BLCO:XNYS), related news, valuation, dividends and more to help you make your investing decisions.

Two modified corticosteroids, rimexolone (Vexol ®, Alcon, Ft. Worth, TX) and loteprednoletabonate (Alrex ® and Lotemax ®, Bausch & Lomb, Rochester, NY), are indicated for short-term treatment ...